Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

Authors: Catherine Diefenbach, Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson, Kevin A. David, Ranjana H. Advani, Timothy S. Fenske, Stefan K. Barta, Neil Palmisiano, Jakub Svoboda, David Morgan, Reem Karmali, Elad Sharon, Howard Streicher, Brad S. Kahl, Stephen M. Ansell - The Lancet 2020 cited by 142